AffyImmune Therapeutics

150 150 ORI Capital

AffyImmune Therapeutics is a New York-based biopharmaceutical company specializing in affinity tuned Chimeric Antigen Receptor (“CAR”) T cell therapy in solid tumors. The Company’s proprietary technology may significantly improve the existing CAR-T cell therapy by extending the target of CAR-T therapies to solid tumors using a novel molecule and tuning down the affinity from picomolar to micromolar level to lower the on-target off-tumor toxicity.